Walleye Capital LLC Alector, Inc. Transaction History

Walleye Capital LLC

$46.2 Billion
Q3 2024

A detailed history of Walleye Capital LLC transactions in Alector, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 204,067 shares of ALEC stock, worth $742,803. This represents 0.0% of its overall portfolio holdings.

Number of Shares

204,067

Previous 278,272 26.67%

Holding current value

$742,803

Previous $1.26 Million 24.62%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.34 - $6.58 $322,049 - $488,268	-74,205 Reduced 26.67%	204,067 $952,000
Q2 2024 Aug 14, 2024	BUY	$4.19 - $6.23 $106,694 - $158,640	25,464 Added 10.07%	278,272 $1.26 Million
Q1 2024 May 15, 2024	SELL	$5.69 - $8.08 $53,019 - $75,289	-9,318 Reduced 3.55%	252,808 $1.52 Million
Q4 2023 Feb 14, 2024	BUY	$3.77 - $8.39 $988,215 - $2.2 Million	262,126 New	262,126 $2.09 Million
Q1 2023 May 15, 2023	SELL	$5.85 - $9.84 $284,877 - $479,178	-48,697 Reduced 44.35%	61,116 $378,000
Q4 2022 Feb 14, 2023	BUY	$6.88 - $9.55 $755,513 - $1.05 Million	109,813 New	109,813 $1.01 Million
Q2 2022 Aug 08, 2022	SELL	$7.65 - $14.24 $114,750 - $213,600	-15,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$13.02 - $20.78 $131,137 - $209,296	-10,072 Reduced 40.17%	15,000 $214,000
Q4 2021 Mar 03, 2022	BUY	$19.35 - $25.54 $184,173 - $243,089	9,518 Added 61.19%	25,072 $517,000
Q3 2021 Nov 15, 2021	BUY	$21.65 - $39.49 $336,744 - $614,227	15,554 New	15,554 $355,000
Q4 2020 Feb 16, 2021	SELL	$9.4 - $16.7 $608,781 - $1.08 Million	-64,764 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$10.54 - $24.96 $682,612 - $1.62 Million	64,764 New	64,764 $682,000

Others Institutions Holding ALEC

# of Institutions

167

Shares Held

57.8M

Call Options Held

146K

Put Options Held

90.8K

View Full List

About Alector, Inc.

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $301M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

More about ALEC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.

Account

Walleye Capital LLC Alector, Inc. Transaction History